NASDAQ:PMD - Psychemedics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$20.05 +0.29 (+1.47 %)
(As of 07/19/2018 08:04 AM ET)
Previous Close$19.76
Today's Range$20.00 - $20.08
52-Week Range$15.99 - $27.41
Volume2,541 shs
Average Volume7,257 shs
Market Capitalization$108.52 million
P/E Ratio22.98
Dividend Yield3.64%
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, synthetic cannabinoids, and benzodiazepines, as well as opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. The company offers its services to employers for applicant and employee testing; treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use; and Fortune 500 companies and small to mid-size corporations, as well as school and government entities. Psychemedics Corporation was founded in 1985 and is headquartered in Acton, Massachusetts.

Receive PMD News and Ratings via Email

Sign-up to receive the latest news and ratings for PMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medical laboratories


Debt-to-Equity Ratio0.11
Current Ratio3.01
Quick Ratio3.01


Trailing P/E Ratio22.98
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$39.70 million
Price / Sales2.77
Cash Flow$1.5376 per share
Price / Cash13.04
Book Value$3.39 per share
Price / Book5.91


EPS (Most Recent Fiscal Year)N/A
Net Income$6.12 million
Net Margins14.52%
Return on Equity26.72%
Return on Assets18.48%


Outstanding Shares5,490,000
Market Cap$108.52

The Truth About Cryptocurrencies

Psychemedics (NASDAQ:PMD) Frequently Asked Questions

What is Psychemedics' stock symbol?

Psychemedics trades on the NASDAQ under the ticker symbol "PMD."

How often does Psychemedics pay dividends? What is the dividend yield for Psychemedics?

Psychemedics announced a quarterly dividend on Tuesday, April 24th. Shareholders of record on Tuesday, May 8th will be paid a dividend of $0.18 per share on Friday, May 18th. This represents a $0.72 annualized dividend and a yield of 3.59%. The ex-dividend date is Monday, May 7th. This is a positive change from Psychemedics's previous quarterly dividend of $0.15. View Psychemedics' Dividend History.

How were Psychemedics' earnings last quarter?

Psychemedics Corp. (NASDAQ:PMD) announced its quarterly earnings results on Tuesday, April, 24th. The company reported $0.23 EPS for the quarter. The company had revenue of $10.94 million for the quarter. Psychemedics had a return on equity of 26.72% and a net margin of 14.52%. View Psychemedics' Earnings History.

When is Psychemedics' next earnings date?

Psychemedics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Psychemedics.

What is the consensus analysts' recommendation for Psychemedics?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Psychemedics in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of Psychemedics' key competitors?

Who are Psychemedics' key executives?

Psychemedics' management team includes the folowing people:
  • Mr. Raymond C. Kubacki Jr., Chairman, Chief Exec. Officer and Pres (Age 73)
  • Mr. James V. Dyke, Corp. VP of Sales & Marketing (Age 53)
  • Dr. Michael I. Schaffer Ph.D., VP of Laboratory Operations (Age 73)
  • Dr. Werner A. Baumgartner Ph.D., Founder
  • Ms. Annette Baumgartner, Founder

Has Psychemedics been receiving favorable news coverage?

News headlines about PMD stock have been trending somewhat positive on Thursday, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Psychemedics earned a media sentiment score of 0.20 on Accern's scale. They also assigned media headlines about the company an impact score of 44.76 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Psychemedics' major shareholders?

Psychemedics' stock is owned by many different of retail and institutional investors. Top institutional investors include Deprince Race & Zollo Inc. (1.07%). Company insiders that own Psychemedics stock include Fred J Weinert, James V Dyke, Michael I Schaffer, Neil Lerner and Raymond C Kubacki Jr. View Institutional Ownership Trends for Psychemedics.

Which institutional investors are buying Psychemedics stock?

PMD stock was acquired by a variety of institutional investors in the last quarter, including Deprince Race & Zollo Inc.. View Insider Buying and Selling for Psychemedics.

How do I buy shares of Psychemedics?

Shares of PMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Psychemedics' stock price today?

One share of PMD stock can currently be purchased for approximately $20.05.

How big of a company is Psychemedics?

Psychemedics has a market capitalization of $108.52 million and generates $39.70 million in revenue each year. Psychemedics employs 231 workers across the globe.

How can I contact Psychemedics?

Psychemedics' mailing address is 289 GREAT ROAD, ACTON MA, 01720. The company can be reached via phone at 978-206-8220.

MarketBeat Community Rating for Psychemedics (NASDAQ PMD)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  90 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  136
MarketBeat's community ratings are surveys of what our community members think about Psychemedics and other stocks. Vote "Outperform" if you believe PMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/19/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.